264 related articles for article (PubMed ID: 21514689)
1. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.
Kothary N; Diak IL; Brinker A; Bezabeh S; Avigan M; Dal Pan G
J Am Acad Dermatol; 2011 Sep; 65(3):546-551. PubMed ID: 21514689
[TBL] [Abstract][Full Text] [Related]
2. Progressive multifocal leukoencephalopathy and reversible progressive leukoencephalopathy syndrome in dermatologic therapy.
Ladizinski B; Heller MM; Bhutani T; Zitelli KB; Koo JY
J Drugs Dermatol; 2013 Feb; 12(2):e20-4. PubMed ID: 23377400
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab.
Gadzia J; Turner J
J Drugs Dermatol; 2010 Aug; 9(8):1005-9. PubMed ID: 20684152
[TBL] [Abstract][Full Text] [Related]
4. Efalizumab discontinuation: a practical strategy.
Pugashetti R; Koo J
J Dermatolog Treat; 2009; 20(3):132-6. PubMed ID: 19459081
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
[TBL] [Abstract][Full Text] [Related]
6. Progressive multifocal leukoencephalopathy and antipsoriatic drugs: assessing the risk of immunosuppressive treatments.
Di Lernia V
Int J Dermatol; 2010 Jun; 49(6):631-5. PubMed ID: 20618466
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
Molloy ES; Calabrese LH
Arthritis Rheum; 2012 Sep; 64(9):3043-51. PubMed ID: 22422012
[TBL] [Abstract][Full Text] [Related]
8. Therapy: Targeted but not trouble-free: efalizumab and PML.
Molloy ES; Calabrese LH
Nat Rev Rheumatol; 2009 Aug; 5(8):418-9. PubMed ID: 19648939
[TBL] [Abstract][Full Text] [Related]
9. Efalizumab.
Talamonti M; Spallone G; Di Stefani A; Costanzo A; Chimenti S
Expert Opin Drug Saf; 2011 Mar; 10(2):239-51. PubMed ID: 21214420
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of 72 patients on prior efalizumab subsequent to the time of voluntary market withdrawal in 2009.
Prater EF; Day A; Patel M; Menter A
J Drugs Dermatol; 2014 Jun; 13(6):712-8. PubMed ID: 24918562
[TBL] [Abstract][Full Text] [Related]
11. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS).
Schmedt N; Andersohn F; Garbe E
Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1216-20. PubMed ID: 22821419
[TBL] [Abstract][Full Text] [Related]
12. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
Montesu MA; Addis GM; Satta R; Cottoni F
G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
[TBL] [Abstract][Full Text] [Related]
13. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies.
Tavazzi E; Ferrante P; Khalili K
Clin Microbiol Infect; 2011 Dec; 17(12):1776-80. PubMed ID: 22082208
[TBL] [Abstract][Full Text] [Related]
14. Progressive multifocal leukoencephalopathy and newer biological agents.
Berger JR
Drug Saf; 2010 Nov; 33(11):969-83. PubMed ID: 20925435
[TBL] [Abstract][Full Text] [Related]
15. Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.
Schwab N; Ulzheimer JC; Fox RJ; Schneider-Hohendorf T; Kieseier BC; Monoranu CM; Staugaitis SM; Welch W; Jilek S; Du Pasquier RA; Brück W; Toyka KV; Ransohoff RM; Wiendl H
Neurology; 2012 Feb; 78(7):458-67; discussion 465. PubMed ID: 22302546
[TBL] [Abstract][Full Text] [Related]
16. Assessing long-term drug safety: lessons (re) learned from raptiva.
Seminara NM; Gelfand JM
Semin Cutan Med Surg; 2010 Mar; 29(1):16-9. PubMed ID: 20430303
[TBL] [Abstract][Full Text] [Related]
17. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.
Carson KR; Focosi D; Major EO; Petrini M; Richey EA; West DP; Bennett CL
Lancet Oncol; 2009 Aug; 10(8):816-24. PubMed ID: 19647202
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
[TBL] [Abstract][Full Text] [Related]
20. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
